A 7-day course of oral moxifloxacin monotherapy successfully treated uncomplicated acute appendicitis, though it did not appear to be noninferior to an intravenous (IV) ertapenem plus oral levofloxacin/metronidazole treatment regimen, according to results of the APPAC* II trial.
Metabolic surgery may be a suitable treatment option for type 2 diabetes (T2D), with a greater likelihood of remission, lower requirement for glucose-control medications, and fewer diabetes-related complications compared with medical therapy, according to long-term follow-up of a small Italian trial.
Adherence to healthful dietary patterns can help reduce the risk of end-stage kidney disease (ESKD) among Asians, particularly among those who are overweight or obese, according to the results of the Singapore Chinese Health Study.
A minimal monitoring (MINMON) approach to treatment of hepatitis C virus (HCV) infection with sofosbuvir/velpatasvir appeared to render an acceptable sustained virological response (SVR), according to results of the phase IV ACTG* A5360 trial.
Adding bemarituzumab to mFOLFOX6 significantly improved survival outcomes and response rate compared with mFOLFOX6 alone in patients FGFR2b-positive, HER2-negative gastric cancer, according to the FIGHT study presented at the 2021 ASCO GI Cancer Symposium.
Results of a single-centre study in the UK have suggested that patients receiving systemic anticancer therapy for gastrointestinal (GI) cancers could continue their treatment during the COVID-19 pandemic.
Treatment with nivolumab led to significantly improved overall survival (OS) in patients with advanced oesophageal squamous cell carcinoma (ESCC), according to updated results of the ATTRACTION-3* study presented at ASCO GI 2021.
In patients with metastatic colorectal cancer (mCRC), the addition of anlotinib to best supportive care did not confer overall survival (OS) benefit, though there was improvement in progression-free survival (PFS), according to results of the phase III ALTER0703 trial presented at ASCO GI 2021.
Treatment with polaprezinc plus proton pump inhibitor (PPI) is noninferior to rebamipide plus PPI in terms of ulcer healing rate at 4 weeks after endoscopic submucosal dissection (ESD), a Korea study has shown.
While early-phase clinical trials may demonstrate substantial levels of overall response rates in patients with relapsed/refractory multiple myeloma (RRMM), high heterogeneity of evidence prevents the accurate assessment of clinical benefit before patient participation, reports a recent meta-analysis.
The COVID-19 vaccine AZD1222 by AstraZeneca and the University of Oxford was 79 percent effective overall in preventing symptomatic infections – higher than observed in previous clinical trials of the vaccine – at the interim analysis of a US phase III trial.
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.